Research

Randomized Control Trial of Essential Amino Acid Supplementation in Protein Deficient Patients Following Total Knee Arthroplasty

IRB Number: 2015-067

Institutional Review Board, Hospital for Special Surgery

May 20, 2015

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

David J. Mayman, MD

Co-Investigators

Michael B. Cross, MD
Seth A. Jerabek, MD
Kaitlin M. Carroll, BS
Joseph Nguyen
Liz Niedbala

Summary

The study will begin when IRB approval is granted and will continue until 50 patients are recruited. Follow-up will be for 1 year after the indexed surgical intervention.

Inclusion/Exclusion Criteria

The study will begin when IRB approval is granted and will continue until 50 patients are recruited. Follow-up will be for 1 year after the indexed surgical intervention.

Contact Information

David J. Mayman MD
maymand@hss.edu
212.774.2024